Dimethaid WF10 fails Phase III for HIV
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Dimethaid is halting development of its HIV/AIDS agent WF10 following the immune regulator's failure to meet primary endpoints in a 96-week, placebo-controlled, double-blind Phase III trial. Results from the North American trial's 229 late-stage AIDS patients "indicated no statistical difference between WF10 and placebo in affecting the time to onset of clinical progression, defined as any new AIDS-defining event or death," the firm says July 14. Dimethaid plans to evaluate the study's secondary results and "re-evaluate WF10's future business potential and its position in the company's long-term development pipeline." The firm notes WF10 (tetrachlorodecaoxygen) may have potential in autoimmune diseases and oncology...
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.